Biologics Contract Manufacturing Market, By Biologic (Antibody-Drug Conjugates, Cell And Gene Therapies, Vaccines, Recombinant Proteins & Enzymes, and Monoclonal Antibodies), By Service Type, By Scale, By Therapeutic Area, By Production, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5094
|
Published Date
April 2026
|
Pages
326
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Biologics Contract Manufacturing Market size was valued at US$ 35,118.82 Million in 2025, expanding at a CAGR of 10.20% from 2026 to 2033.
Biologics contract manufacturing refers to the outsourcing of biologics production—such as cell therapies, gene therapies, recombinant proteins, and vaccines—to specialized contract manufacturing organizations (CMOs). These organizations provide the expertise, infrastructure, and advanced technologies required to produce complex medicines derived from living systems. This model enables pharmaceutical companies to reduce operational risk, access specialized capabilities, and accelerate the delivery of therapies to patients in a more efficient and cost-effective manner.
The biologics contract manufacturing market is driven by the increasing number of biologic therapy approvals and the implementation of stringent regulatory and quality standards in pharmaceutical manufacturing. The U.S. Food and Drug Administration (FDA) continues to strengthen biologics-related guidance, expand facility inspections, and support accelerated approval pathways, all of which encourage greater reliance on outsourcing partnerships globally. In addition, the FDA reported approximately 44 novel drug approvals in 2024, a significant portion of which included biologics and advanced therapies. This rising approval rate is further increasing the demand for external manufacturing capacity, thereby supporting continued growth in the biologics contract manufacturing sector.
Biologics Contract Manufacturing Market- Market Dynamics
Growing Global Demand for Biologic Therapies
The rapid expansion of biologic therapies remains one of the most significant long-term growth drivers for the biologics contract manufacturing market. Unlike traditional small-molecule drugs, biologics are complex therapies derived from living systems and are increasingly being used in the treatment of oncology, autoimmune disorders, rare diseases, and infectious diseases due to their targeted and effective clinical outcomes. Regulatory approval trends further reinforce this growth, with biologics consistently accounting for around one-third of recent U.S. FDA drug approvals and reaching approximately 40% in certain years, underscoring their growing importance in modern healthcare.
This expanding development pipeline is placing considerable pressure on manufacturing capacity, particularly for biotech companies that often lack the financial resources and technical infrastructure required to establish dedicated biologics production facilities. As a result, contract manufacturing organizations (CMOs) are becoming essential partners for pharmaceutical and biotech companies by providing specialized expertise, advanced technologies, and scalable production capabilities. Their involvement helps reduce operational burdens, accelerates time-to-market for new biologic therapies, and ensures a reliable and consistent supply of critical medicines.
Biologics Contract Manufacturing Market- Segmentation Analysis:
The Global Biologics Contract Manufacturing Market is segmented on the basis of Biologic, Service Type, Scale, Therapeutic Area, Production, and Region.
Within biologic segments, monoclonal antibodies (mAbs) represent a major class of targeted therapies designed to identify and bind to specific disease-related cells or proteins. This high level of specificity makes them widely used in the treatment of cancer, autoimmune disorders, infectious diseases, and rare conditions. Their proven clinical effectiveness and expanding therapeutic applications continue to drive strong and sustained demand. Leading contract development and manufacturing organizations (CDMOs) are steadily expanding their capabilities in this area. For example, Lonza generates a significant share of its biologics revenue from monoclonal antibodies and related bioconjugates, highlighting the commercial strength of this segment. Similarly, WuXi Biologics has significantly increased its mammalian cell culture capacity to support large-scale antibody production for global pharmaceutical clients. As a result, monoclonal antibodies remain one of the most reliable and scalable opportunities in biologics contract manufacturing.
Based on manufacturing scale, the market is segmented into preclinical, commercial, and flexible or multi-scale facilities. Among these, the commercial segment plays a particularly important role. Once biologic drugs receive regulatory approval, they require large-scale, validated production systems with consistent quality and long-term supply assurance, which increases dependence on commercial CDMO partners. This stage supports sustained manufacturing demand for products such as monoclonal antibodies, vaccines, recombinant proteins, and biosimilars over extended periods. Industry developments further reinforce this trend. Samsung Biologics reported full utilization across Plants 1–4 in 2025, contributing to annual CDMO revenue of KRW 4,557 billion, reflecting strong demand for commercial-scale manufacturing. Similarly, Lonza has noted that large pharmaceutical companies account for a significant portion of CDMO revenues, primarily driven by commercial manufacturing activities supported by consistently high utilization of its biologics production facilities.
Biologics Contract Manufacturing Market- Geographical Insights
As healthcare systems increasingly prioritize biologic therapies, regional capabilities in regulatory compliance, manufacturing capacity, and access to advanced technologies are becoming critical factors shaping the future of the biologics contract manufacturing market.
North America is expected to remain a leading region in this market, supported by strong regulatory oversight and sustained innovation. The U.S. Food and Drug Administration (FDA) reported 44 novel drug approvals in 2024, including multiple biologics and advanced therapies that require specialized outsourced manufacturing support, reinforcing steady demand for certified CDMO infrastructure. In addition, U.S. policy emphasis on strengthening domestic pharmaceutical production has encouraged reshoring initiatives, further boosting demand for local manufacturing capabilities. For example, Thermo Fisher Scientific has secured multiple contracts linked to U.S. reshoring efforts, reflecting a broader industry shift as pharmaceutical companies relocate portions of production from Europe and Asia back to the United States. This combination of strong regulatory frameworks, policy support, and advanced manufacturing infrastructure continues to reinforce North America’s leadership in the biologics market.
At the same time, the Asia-Pacific region is emerging as a dynamic growth hub for biopharmaceutical development and manufacturing. Countries such as China, India, and South Korea are rapidly expanding their biopharma capabilities, contributing significantly to the global biologics pipeline and contract manufacturing services. This regional expansion is strengthening Asia-Pacific’s position as a key contributor to global biologics production capacity.
Indonesia Biologics Contract Manufacturing Market- Country Insights
Indonesia is steadily emerging as a growing participant in the biologics contract manufacturing landscape, supported by efforts to strengthen domestic biopharmaceutical capabilities and promote technology transfer in line with national healthcare self-sufficiency goals. Government support through BPOM certification and broader policy initiatives has enabled local companies to develop facilities that meet international compliance standards.
A notable example is PT Etana Biotechnologies, which operates a BPOM-certified biopharmaceutical manufacturing facility inaugurated with presidential support, aimed at expanding domestic production of vaccines and biologics. In parallel, Kalbio Global Medika is contributing to the development of Indonesia’s contract manufacturing ecosystem through cGMP-compliant biologics production, including monoclonal antibodies, biosimilars, and fill-finish services for both domestic and international markets. These developments reflect Indonesia’s broader strategy to strengthen healthcare resilience, reduce dependence on imported biologics, and build a more robust regional supply chain. As regulatory frameworks mature, infrastructure expands, and industry partnerships increase, Indonesia is gradually establishing a sustainable biologics manufacturing base capable of supporting long-term domestic demand as well as broader Southeast Asian needs.
Biologics Contract Manufacturing Market- Competitive Landscape:
The increasing complexity of biologic medicines is steadily driving greater reliance on specialized contract development and manufacturing organizations (CDMOs). As a result, many pharmaceutical and biotechnology companies prefer outsourcing production rather than investing in capital-intensive in-house manufacturing facilities. This shift has enabled leading service providers such as Lonza, Samsung Biologics, WuXi Biologics, Thermo Fisher Scientific, and Catalent to expand their end-to-end capabilities across biologic development and manufacturing.
These organizations support the production of biologics from early-stage clinical batches through to commercial-scale manufacturing, engaging clients through direct partnerships, strategic alliances, and long-term collaboration agreements. For example, Samsung Biologics’ acquisition of a U.S. manufacturing facility from GSK for USD 280 million highlights how major players are expanding global capacity to meet sustained demand. Similarly, established manufacturers such as Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, AGC Biologics, and Vetter Pharma continue to invest in advanced technologies and infrastructure to strengthen their service offerings. In addition, companies are increasingly forming long-term manufacturing agreements and strategic collaborations that ensure stable production pipelines while reducing operational risk for clients. This evolving model reflects a broader industry shift in which CDMOs are viewed as integrated extensions of pharmaceutical companies’ internal manufacturing capabilities, allowing sponsors to focus more on innovation while relying on external partners for scalable and compliant production.
Recent Developments:
- In July 2025, Lonza reported strong business momentum, with its core biologics CDMO segment achieving significant revenue growth in the first half of the year. This performance reflects the company’s ongoing strategic investments in biologics manufacturing capacity and advanced production capabilities, reinforcing its position as a key global biologics manufacturing partner.
- In October 2025, Samsung Biologics secured multiple manufacturing contracts with leading Japanese pharmaceutical companies, completing agreements with four major firms and continuing discussions for additional partnerships. This expansion strengthens its global manufacturing footprint and enhances long-term supply commitments within the biologics contract manufacturing sector.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie, Inc.
- Abzena Ltd.
- Acino International AG
- ADMA Biologics, Inc.
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Avid Bioservices, Inc.
- Baxter International, Inc
- Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
- Cambrex Corporation
- Catalent, Inc.
- Emergent BioSolutions, Inc.
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
- JSR Life Sciences, LLC by JSR Group
- Kemwell Biopharma Pvt. Ltd.
- Lonza Group Ltd.
- Midas Pharma GmbH
- ProBioGen AG
- Recipharm AB
- Rentschler Biopharma SE
- Samsung Biologics
- Thermo Fisher Scientific, Inc.
- Toyobo Co. Ltd.
- Wacker Chemie AG
- WuXi Biologics Co., Ltd.
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY BIOLOGIC- MARKET ANALYSIS, 2020 - 2033
- Antibody-Drug Conjugates
- Cell And Gene Therapies
- Vaccines
- Recombinant Proteins & Enzymes
- Monoclonal Antibodies
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2020 - 2033
- Analytical And Quality Control
- Fill-Finish & Packaging Services
- Packaging
- Labeling And Ancillary Services
- Durg Substance
- Process Development & Tech Transfer
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY SCALE- MARKET ANALYSIS, 2020 - 2033
- Preclinical Scale
- Commercial
- Flexible or Multi-Scale Facilities
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033
- Oncology
- Immunology And Autoimmune Disorders
- Infectious Diseases & Vaccinology
- Cardiovascular And Renal Disorder
- Neurology And Central Nervous System
- Metabolic And Endocrine Disorders
- Respiratory Disorders
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY PRODUCTION- MARKET ANALYSIS, 2020 - 2033
- Mammalian Systems
- Microbial System
- Alternative System
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Biologics Contract Manufacturing Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Biologics Contract Manufacturing Market Snippet by Biologic
2.1.2. Biologics Contract Manufacturing Market Snippet by Service Type
2.1.3. Biologics Contract Manufacturing Market Snippet by Scale
2.1.4. Biologics Contract Manufacturing Market Snippet by Therapeutic Area
2.1.5. Biologics Contract Manufacturing Market Snippet by Production
2.1.6. Biologics Contract Manufacturing Market Snippet by Country
2.1.7. Biologics Contract Manufacturing Market Snippet by Region
2.2. Competitive Insights
3. Biologics Contract Manufacturing Key Market Trends
3.1. Biologics Contract Manufacturing Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Biologics Contract Manufacturing Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Biologics Contract Manufacturing Market Opportunities
3.4. Biologics Contract Manufacturing Market Future Trends
4. Biologics Contract Manufacturing Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Biologics Contract Manufacturing Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Biologics Contract Manufacturing Market Landscape
6.1. Biologics Contract Manufacturing Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Biologics Contract Manufacturing Market – By Biologic
7.1. Overview
7.1.1. Segment Share Analysis, By Biologic, 2025 & 2033 (%)
7.1.2. Antibody-Drug Conjugates
7.1.3. Cell And Gene Therapies
7.1.4. Vaccines
7.1.5. Recombinant Proteins & Enzymes
7.1.6. Monoclonal Antibodies
7.1.7. Others
8. Biologics Contract Manufacturing Market – By Service Type
8.1. Overview
8.1.1. Segment Share Analysis, By Service Type, 2025 & 2033 (%)
8.1.2. Analytical And Quality Control
8.1.3. Fill-Finish & Packaging Services
8.1.4. Packaging
8.1.5. Labeling And Ancillary Services
8.1.6. Durg Substance
8.1.7. Process Development & Tech Transfer
9. Biologics Contract Manufacturing Market – By Scale
9.1. Overview
9.1.1. Segment Share Analysis, By Scale, 2025 & 2033 (%)
9.1.2. Preclinical Scale
9.1.3. Commercial
9.1.4. Flexible Or Multi-Scale Facilities
10. Biologics Contract Manufacturing Market – By Therapeutic Area
10.1. Overview
10.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
10.1.2. Oncology
10.1.3. Immunology And Autoimmune Disorders
10.1.4. Infectious Diseases & Vaccinology
10.1.5. Cardiovascular And Renal Disorder
10.1.6. Neurology And Central Nervous System
10.1.7. Metabolic And Endocrine Disorders
10.1.8. Respiratory Disorders
10.1.9. Others
11. Biologics Contract Manufacturing Market – By Production
11.1. Overview
11.1.1. Segment Share Analysis, By Production, 2025 & 2033 (%)
11.1.2. Mammalian Systems
11.1.3. Microbial System
11.1.4. Alternative System
11.1.5. Others
12. Biologics Contract Manufacturing Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
12.2. North America
12.2.1. Overview
12.2.2. Biologics Contract Manufacturing Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.2.4. North America Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.2.5. North America Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.2.6. North America Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.2.7. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.2.8. North America Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Biologics Contract Manufacturing Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.8. Europe Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.11.7. France Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.18. Denmark
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.18.3. Denmark Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.18.4. Denmark Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.18.5. Denmark Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.18.6. Denmark Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.18.7. Denmark Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.3.19. Rest of Europe
12.3.19.1. Overview
12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.3.19.3. Rest of the Europe Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.3.19.4. Rest of the Europe Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.3.19.5. Rest of the Europe Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.3.19.6. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.3.19.7. Rest of the Europe Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Biologics Contract Manufacturing Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.8. APAC Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.9.7. China Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.10.7. India Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.17. Taiwan
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.17.3. Taiwan Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.17.4. Taiwan Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.17.5. Taiwan Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.17.6. Taiwan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.17.7. Taiwan Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.18. Vietnam
12.4.18.1. Overview
12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.18.3. Vietnam Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.18.4. Vietnam Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.18.5. Vietnam Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.18.6. Vietnam Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.18.7. Vietnam Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.4.19. Rest of APAC
12.4.19.1. Overview
12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.4.19.3. Rest of APAC Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.4.19.4. Rest of APAC Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.4.19.5. Rest of APAC Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.4.19.6. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.4.19.7. Rest of APAC Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Biologics Contract Manufacturing Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.5.8. LATAM Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Biologics Contract Manufacturing Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.15. Iran
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.15.3. Iran Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.15.4. Iran Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.15.5. Iran Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.15.6. Iran Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.15.7. Iran Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.16. Qatar
12.6.16.1. Overview
12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.16.3. Qatar Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.16.4. Qatar Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.16.5. Qatar Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.16.6. Qatar Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.16.7. Qatar Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
12.6.17. Rest of MEA
12.6.17.1. Overview
12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
12.6.17.3. Rest of MEA Market Size and Forecast, By Biologic, 2020 - 2033 (US$ Million)
12.6.17.4. Rest of MEA Market Size and Forecast, By Service Type, 2020 - 2033 (US$ Million)
12.6.17.5. Rest of MEA Market Size and Forecast, By Scale, 2020 - 2033 (US$ Million)
12.6.17.6. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
12.6.17.7. Rest of MEA Market Size and Forecast, By Production, 2020 - 2033 (US$ Million)
13. Key Vendor Analysis- Biologics Contract Manufacturing Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. AbbVie, Inc.
13.2.2. Abzena Ltd.
13.2.3. Acino International AG
13.2.4. ADMA Biologics, Inc.
13.2.5. AGC Biologics
13.2.6. Ajinomoto Bio-Pharma Services
13.2.7. Avid Bioservices, Inc.
13.2.8. Baxter International, Inc
13.2.9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
13.2.10. Cambrex Corporation
13.2.11. Catalent, Inc.
13.2.12. Emergent BioSolutions, Inc.
13.2.13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
13.2.14. JSR Life Sciences, LLC by JSR Group
13.2.15. Kemwell Biopharma Pvt. Ltd.
13.2.16. Lonza Group Ltd.
13.2.17. Midas Pharma GmbH
13.2.18. ProBioGen AG
13.2.19. Recipharm AB
13.2.20. Rentschler Biopharma SE
13.2.21. Samsung Biologics
13.2.22. Thermo Fisher Scientific, Inc.
13.2.23. Toyobo Co. Ltd.
13.2.24. Wacker Chemie AG
13.2.25. WuXi Biologics Co., Ltd.
13.2.26. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- AbbVie, Inc.
- Abzena Ltd.
- Acino International AG
- ADMA Biologics, Inc.
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Avid Bioservices, Inc.
- Baxter International, Inc
- Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
- Cambrex Corporation
- Catalent, Inc.
- Emergent BioSolutions, Inc.
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
- JSR Life Sciences, LLC by JSR Group
- Kemwell Biopharma Pvt. Ltd.
- Lonza Group Ltd.
- Midas Pharma GmbH
- ProBioGen AG
- Recipharm AB
- Rentschler Biopharma SE
- Samsung Biologics
- Thermo Fisher Scientific, Inc.
- Toyobo Co. Ltd.
- Wacker Chemie AG
- WuXi Biologics Co., Ltd.
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY BIOLOGIC- MARKET ANALYSIS, 2020 - 2033
- Antibody-Drug Conjugates
- Cell And Gene Therapies
- Vaccines
- Recombinant Proteins & Enzymes
- Monoclonal Antibodies
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2020 - 2033
- Analytical And Quality Control
- Fill-Finish & Packaging Services
- Packaging
- Labeling And Ancillary Services
- Durg Substance
- Process Development & Tech Transfer
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY SCALE- MARKET ANALYSIS, 2020 - 2033
- Preclinical Scale
- Commercial
- Flexible or Multi-Scale Facilities
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033
- Oncology
- Immunology And Autoimmune Disorders
- Infectious Diseases & Vaccinology
- Cardiovascular And Renal Disorder
- Neurology And Central Nervous System
- Metabolic And Endocrine Disorders
- Respiratory Disorders
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY PRODUCTION- MARKET ANALYSIS, 2020 - 2033
- Mammalian Systems
- Microbial System
- Alternative System
- Others
GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
